Zahid Jawad Ahmad, Henning Mattias A S, Bouazzi Dorra, Jemec Gregor B E
Department of Surgery, Center for Surgical Science, Zealand University Hospital, University of Copenhagen, Copenhagen, Denmark.
Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
Dermatology. 2024 Dec 23:1-10. doi: 10.1159/000537920.
Hidradenitis suppurativa (HS), a chronic inflammatory skin disease affecting intertriginous areas, presents a recurring and debilitating challenge. Even though recent efforts have been made to estimate the overall HS prevalence, variations in screening modalities and missing data from the Global South warrant further investigation. Understanding the HS prevalence is crucial for treatment approaches and pathogenesis. Thus, we aimed to estimate a global HS prevalence based on studies using homogeneous validated questions.
This systematic review was prospectively registered on PROSPERO and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in PubMed, Embase, and CINAHL were performed on August 9, 2023. Original reports assessing the HS prevalence in adults using the following two questions were included: "Do you have recurrent boils of the skin?" and "Have you for the past 6 months had 2 or more boils/abscesses in any of the below locations: in the axilla, in the groin, around your genitals, on the buttocks, several locations i.e., first the buttocks then the axilla, etc.?" A pooled prevalence with 95% confidence interval (CI) was calculated with a random-effects model.
Eight studies qualified for inclusion, of which the prevalence estimate ranged from 0.7% to 6.4%. The meta-analysis encompassing 49,971 participants revealed a global HS prevalence of 2.5% (95% CI, 1.8-3.5%).
This meta-analysis suggests a global HS prevalence of 2.5% using a validated questionnaire. Due to heterogeneity and sparse data from the Global South, this estimate should be interpreted with caution.
化脓性汗腺炎（HS）是一种影响皮肤褶皱部位的慢性炎症性皮肤病，带来了反复且使人衰弱的挑战。尽管最近已努力估计HS的总体患病率，但筛查方式的差异以及来自全球南方的数据缺失仍需进一步调查。了解HS患病率对于治疗方法和发病机制至关重要。因此，我们旨在基于使用统一验证问题的研究来估计全球HS患病率。
本系统评价已在PROSPERO上进行前瞻性注册，并遵循系统评价和Meta分析的首选报告项目（PRISMA）指南。于2023年8月9日在PubMed、Embase和CINAHL中进行检索。纳入使用以下两个问题评估成人HS患病率的原始报告：“您是否有复发性皮肤疖肿？”以及“在过去6个月内，您在以下任何部位是否有2个或更多的疖肿/脓肿：腋窝、腹股沟、生殖器周围、臀部，或多个部位（即先臀部后腋窝等）？”采用随机效应模型计算合并患病率及95%置信区间（CI）。
八项研究符合纳入标准，患病率估计范围为0.7%至6.4%。纳入49,971名参与者的Meta分析显示，全球HS患病率为2.5%（95%CI，1.8 - 3.5%）。
这项Meta分析表明，使用经过验证的问卷得出全球HS患病率为2.5%。由于存在异质性以及来自全球南方的数据稀少，对这一估计结果应谨慎解读。
